glp 1 for people who are not obese if GLP-1 medications changing the conversation around obesity care—but Beyond Weight Loss: ED Implications

2022Oct;15(189):15562

Health regulatory agencies such as the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency of Japan (PMDA) evaluate data from clinical trials before approving the use of GLP-1 analogs for the treatment of diabetes and obesity

The most common GLP-1 injections available in the UK include semaglutide (sold as Wegovy for weight loss and Ozempic for diabetes), liraglutide (Saxenda), and tirzepatide (Mounjaro)

B., Ayaz, T., Sumer, F., Ilkkilic, K

Drug manufacturers must prove their products are safe and effective before selling them

In brief, the gradient started with 5% buffer B and increased stepwise to 45% over 45 min, followed by a wash-out at 95% buffer B, all at a flowrate of 300 nl min 1